• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[法国尼斯地区慢性炎症性肠病患者丙型肝炎患病率及危险因素评估]

[Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors].

作者信息

Longo F, Hebuterne X, Tran A, Staccini P, Hastier P, Schneider S, Benzaken S, Tirtaine C, Rampal P

机构信息

Fédération des Maladies de l'Appareil Digestif, Hôpital de l'Archet II, CHU, Nice.

出版信息

Gastroenterol Clin Biol. 2000 Jan;24(1):77-81.

PMID:10679588
Abstract

OBJECTIVES

To estimate the prevalence of viral hepatitis C markers and to determine independent risk factors in a population of patients with inflammatory bowel disease.

METHODS

We studied 117 consecutive out-patients (male/female, 53/64; mean age 41 +/- 16 yrs) with ulcerative colitis (43 patients) or Crohn's disease (74 patients). Anti-hepatitis C virus antibodies were tested with a third generation Elisa test. The following risk factors were tested for each patient: duration of inflammatory bowel disease, number of colonoscopies, history of surgical procedures, blood transfusions, intravenous drug abuse and immunosuppressive treatments.

RESULTS

The seroprevalence of hepatitis C virus was 5.98% (7/117). The only risk factor independently associated with serological markers for hepatitis C virus was blood transfusion (odds ratio: 7.77; confidence interval: 95% (1.63-49.09); P=0.012).

CONCLUSIONS

The prevalence of hepatitis C virus infection was high in patients with inflammatory bowel disease, mainly due to blood transfusions. Colonoscopies and surgical procedures were not found to be additional risk factors for infection with hepatitis C virus.

摘要

目的

评估丙型病毒性肝炎标志物的患病率,并确定炎症性肠病患者群体中的独立危险因素。

方法

我们研究了117例连续性门诊患者(男/女,53/64;平均年龄41±16岁),其中溃疡性结肠炎患者43例,克罗恩病患者74例。采用第三代酶联免疫吸附试验检测抗丙型肝炎病毒抗体。对每位患者检测以下危险因素:炎症性肠病病程、结肠镜检查次数、手术史、输血史、静脉注射毒品史和免疫抑制治疗史。

结果

丙型肝炎病毒血清阳性率为5.98%(7/117)。与丙型肝炎病毒血清学标志物独立相关的唯一危险因素是输血(优势比:7.77;置信区间:95%(1.63 - 49.09);P = 0.012)。

结论

炎症性肠病患者中丙型肝炎病毒感染患病率较高,主要原因是输血。未发现结肠镜检查和手术是丙型肝炎病毒感染的额外危险因素。

相似文献

1
[Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors].[法国尼斯地区慢性炎症性肠病患者丙型肝炎患病率及危险因素评估]
Gastroenterol Clin Biol. 2000 Jan;24(1):77-81.
2
Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study.西班牙炎症性肠病患者中乙型和丙型肝炎的患病率及相关因素:一项全国性多中心研究
Am J Gastroenterol. 2009 Jan;104(1):57-63. doi: 10.1038/ajg.2008.4.
3
[Epidemiological information obtained from anti-hepatitis C virus screening in blood donors and candidates for autologous transfusion from 1992 to 1996 in the Alpes-Maritimes region].[1992年至1996年在滨海阿尔卑斯省地区对献血者和自体输血候选者进行抗丙型肝炎病毒筛查所获得的流行病学信息]
Gastroenterol Clin Biol. 2000 Mar;24(3):337-41.
4
Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.干扰素-α治疗对慢性丙型肝炎合并炎症性肠病患者是否安全有效?一项病例对照研究。
Aliment Pharmacol Ther. 2005 Aug 1;22(3):209-15. doi: 10.1111/j.1365-2036.2005.02556.x.
5
Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study.保加利亚健康人群中丙型肝炎病毒抗体流行率及与乙型肝炎病毒合并感染情况。一项血清流行病学研究。
Minerva Gastroenterol Dietol. 2004 Mar;50(1):89-96.
6
[Prevalence and incidence of hepatitis C seroconversion in patients on hemodialysis].[血液透析患者丙型肝炎血清学转换的患病率和发病率]
Acta Med Croatica. 2003;57(1):39-42.
7
[Prevalence of hepatitis A, B, C virus markers in Réunion (south hospital and Saint Pierre prison)].[留尼汪岛(南医院和圣皮埃尔监狱)甲型、乙型、丙型肝炎病毒标志物的流行情况]
Bull Soc Pathol Exot. 2000 Feb;93(1):34-40.
8
Alcoholism is associated with hepatitis C but not hepatitis B in an urban population.在城市人口中,酗酒与丙型肝炎有关,但与乙型肝炎无关。
Am J Gastroenterol. 1996 Mar;91(3):498-505.
9
Factors associated to the prevalence of antibodies to hepatitis C virus among patients receiving hemodialysis at selected dialysis centers in Puerto Rico, 2005.2005年波多黎各选定透析中心接受血液透析患者中丙型肝炎病毒抗体流行率的相关因素。
P R Health Sci J. 2009 Mar;28(1):18-23.
10
Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London.伦敦南部一个种族多样的HIV-1感染队列中丙型肝炎的患病率。
HIV Med. 2005 May;6(3):206-15. doi: 10.1111/j.1468-1293.2005.00291.x.

引用本文的文献

1
Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis.炎症性肠病患者中乙型肝炎病毒和丙型肝炎病毒感染的患病率:一项系统评价和荟萃分析。
Intest Res. 2023 Jul;21(3):392-405. doi: 10.5217/ir.2022.00094. Epub 2022 Dec 2.
2
Core indicators of an evaluation and guidance system for quality of care in inflammatory bowel disease centers: A critical review.炎症性肠病中心医疗质量评估与指导系统的核心指标:一项批判性综述。
EClinicalMedicine. 2022 Apr 7;46:101382. doi: 10.1016/j.eclinm.2022.101382. eCollection 2022 Apr.
3
Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C.
慢性丙型肝炎合并炎症性肠病患者肝脏硬度的变化趋势
Diagnostics (Basel). 2020 Dec 2;10(12):1037. doi: 10.3390/diagnostics10121037.
4
Chronic Viral Hepatitis in a Cohort of Inflammatory Bowel Disease Patients from Southern Italy: A Case-Control Study.意大利南部炎性肠病患者队列中的慢性病毒性肝炎:一项病例对照研究。
Pathogens. 2020 Oct 23;9(11):870. doi: 10.3390/pathogens9110870.
5
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver.抗肿瘤坏死因子-α(TNF-α)对肝脏的有害影响和潜在益处。
Int J Mol Sci. 2018 Jul 27;19(8):2199. doi: 10.3390/ijms19082199.
6
Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India.印度北部炎症性肠病患者中乙型肝炎、丙型肝炎和人类免疫缺陷病毒感染的患病率。
Intest Res. 2017 Jan;15(1):97-102. doi: 10.5217/ir.2017.15.1.97. Epub 2017 Jan 31.
7
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?管理炎症性肠病患者感染筛查和疫苗接种的最佳方法是什么?
World J Gastrointest Pharmacol Ther. 2016 Aug 6;7(3):387-96. doi: 10.4292/wjgpt.v7.i3.387.
8
Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.乙型肝炎和炎症性肠病:抗病毒预防的作用。
World J Gastroenterol. 2013 Mar 7;19(9):1342-8. doi: 10.3748/wjg.v19.i9.1342.
9
The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.抗 TNF 治疗对炎症性肠病患者慢性丙型肝炎病毒感染病程的影响。
Dig Dis Sci. 2013 Apr;58(4):1149-56. doi: 10.1007/s10620-012-2457-0. Epub 2012 Nov 20.
10
Hepatitis C virus and inflammatory bowel disease.丙型肝炎病毒与炎症性肠病
Dig Dis Sci. 2009 Jun;54(6):1171-7. doi: 10.1007/s10620-008-0489-2. Epub 2008 Oct 31.